Deucrictibant is a proposed oral, on demand, treatment for HAE attacks. There is currently a study underway – The Deucrictibant Study – and they are open for recruitment of patients now.
The team are looking for patients aged over 12 to participate in the study. Patients can be on long term prophylaxis as long as they still have acute attacks.
The study involves 3 visits in all and some blood tests with opportunity for long-term treatment with Deucrictibant after the study. It would be good for anyone who really dislikes the available acute injections.
If you would like more information you are able to contact Pamela Burton at : Pamela.Burton@health.nsw.gov.au